Patents Examined by Manjunath N. Rao
  • Patent number: 10828260
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • Patent number: 10829525
    Abstract: In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.
    Type: Grant
    Filed: March 8, 2017
    Date of Patent: November 10, 2020
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Jonathan Barasch, Andong Qiu
  • Patent number: 10818377
    Abstract: Described herein are polypeptides capable of self-assembling to form homo-oligomers, and methods for designing such polypeptides.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: October 27, 2020
    Assignee: University of Washington
    Inventors: David Baker, Jorge Fallas, George Ueda, William H. Sheffler, Vanessa Nguyen
  • Patent number: 10808262
    Abstract: The invention provides non-naturally occurring microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing carbon flux through acetyl-CoA. In some embodiments, the microbial organisms having such pathways also include pathways for generating reducing equivalents, formaldehyde fixation and/or formate assimilation. The enhanced carbon flux through acetyl-CoA, in combination with pathways for generating reducing equivalents, formaldehyde fixation and/or formate assimilation can, in some embodiments, be used for production of a bioderived compound. Accordingly, in some embodiments, the microbial organisms of the invention can include a pathway capable of producing a bioderived compound of the invention.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: October 20, 2020
    Assignee: Genomatica, Inc.
    Inventors: Robin E. Osterhout, Anthony P. Burgard, Priti Pharkya, Stefan Andrae
  • Patent number: 10793882
    Abstract: The invention provides non-naturally occurring microbial organisms having a toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene pathway. The invention additionally provides methods of using such organisms to produce toluene, benzene, p-toluate, terephthalate, (2-hydroxy-3-methyl-4-oxobutoxy)phosphonate, (2-hydroxy-4-oxobutoxy)phosphonate, benzoate, styrene, 2,4-pentadienoate, 3-butene-1ol or 1,3-butadiene.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: October 6, 2020
    Assignee: Genomatica, Inc.
    Inventors: Robin E. Osterhout, Anthony P. Burgard, Priti Pharkya, Mark J. Burk
  • Patent number: 10787651
    Abstract: A Bradyrhizobium monooxygenase, a gene for encoding the monooxygenase, a recombinant expression vector comprising the gene and a recombinant transformant, a method of preparing the monooxygenase by the recombinant expression transformant, and a method of preparing an optically pure chiral sulfoxide by the monooxygenase, in particular to a method of preparing prazole drugs by means of catalyzing the asymmetric oxidation of thioether, a prazole precursor. As compared with other methods of preparing an optically pure sulfoxide, the product produced by the monooxygenase of the present invention as a catalyst has high optical purity, avoids the generation of the byproduct sulfone, and has advantages of mild reaction conditions, simple and convenient operations, easy amplification, etc.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: September 29, 2020
    Assignees: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Huilei Yu, Yan Zhang, Jianhe Xu, Qian Zhao, Jiang Pan, Feng Liu, Guoqiang Lin
  • Patent number: 10774124
    Abstract: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: September 15, 2020
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Richard T. Lee, Vincent Segers
  • Patent number: 10745674
    Abstract: The present invention relates to methods for producing polyketide synthase variants, and for altering the activity and/or substrate specificity of putative native and variant polyketide synthases. The present invention further relates to compositions comprising said polyketide synthase variants, compounds prepared using said polyketide synthase variants, and uses of said polyketide synthase variants. In one embodiment, said polyketide synthase variant is 2-pyrone synthase.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: August 18, 2020
    Assignees: SALK INSTITUTE FOR BIOLOGICAL STUDIES, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Joseph Noel, Kate Woods, Marianne Bowman, Gordon Louie, Nancy Anderson Da Silva, Javier Pascual Cardenas
  • Patent number: 10745464
    Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: August 18, 2020
    Assignee: The Regents of the University of California
    Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Ruth Bertozzi
  • Patent number: 10717972
    Abstract: The present disclosure provides a genetically modified host cell capable of producing linalool (or 3,7-dimethylocta-1,6-dien-3-ol).
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 21, 2020
    Assignee: The Regents of the University of California
    Inventors: Charles M. Denby, Jay D. Keasling, James Kirby, Rachel Alexandra Li
  • Patent number: 10711256
    Abstract: Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: July 14, 2020
    Assignee: Duke University
    Inventors: Charles Gersbach, David Ousterout
  • Patent number: 10704069
    Abstract: The current disclosure provides a process for enzymatically converting a saccharide into allulose. The invention also relates to a process for preparing allulose where the process involves converting fructose 6-phosphate (F6P) to allulose 6-phosphate (A6P), catalyzed by allulose 6-phosphate 3-epimerase (A6PE), and converting the A6P to allulose, catalyzed by allulose 6-phosphate phosphatase (A6PP).
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: July 7, 2020
    Assignee: BONUMOSE LLC
    Inventors: Daniel Joseph Wichelecki, Edwin O. Rogers
  • Patent number: 10689425
    Abstract: This invention relates to collagen-binding synthetic peptidoglycans and engineered collagen matrices comprising a collagen matrix and a collagen-binding synthetic peptidoglycan where the collagen-binding synthetic peptidoglycan can be aberrant or can have amino acid homology with a portion of the amino acid sequence of a protein or a proteoglycan that regulates collagen fibrillogenesis. The invention also relates to kits, compounds, compositions, and engineered graft constructs comprising such collagen-binding synthetic peptidoglycans or engineered collagen matrices and methods for their preparation and use.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: June 23, 2020
    Assignee: Purdue Research Foundation
    Inventors: Alyssa Panitch, John Eric Paderi, Kinam Park, Katherine Allison Stuart, Steve Higbee
  • Patent number: 10640757
    Abstract: The present invention relates to a method for constructing a host cell expressing a polypeptide of interest from at least two ORF's stably integrated onto the chromosome of the host cell comprising the steps of: a) providing the at least two ORF's encoding the same polypeptide, wherein the at least two DNA sequences of the ORF's differ in at least one position; b) integrating the at least two ORF's in the same orientation on the host cell chromosome.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: May 5, 2020
    Assignee: Novozymes A/S
    Inventors: Steen Troels Jorgensen, Poul Erik Pedersen
  • Patent number: 10597644
    Abstract: Disclosed are DNA polymerases having increased reverse transcriptase efficiency, mismatch tolerance, extension rate and/or tolerance of RT and polymerase inhibitors relative to a corresponding, unmodified polymerase. The polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the DNA polymerases.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 24, 2020
    Assignee: Roche Molecular Systems, Inc.
    Inventors: Keith Bauer, Thomas W. Myers, Fred Reichert, Joseph San Filippo, Rachel Shahinian, Shawn Suko
  • Patent number: 10584358
    Abstract: The present invention is directed to methods and compositions for typing of Lactobacillus buchneri bacterial strains, detecting the presence of a L. buchneri in a sample, identifying a strain of L. buchneri having resistance to an invasive foreign genetic element, modifying the resistance of bacteria and archeae to an invasive foreign genetic element, and introducing nicks into or cleaving double stranded DNA for genome editing.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: March 10, 2020
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Rodolphe Barrangou, Alexandra E. Briner
  • Patent number: 10584150
    Abstract: Modified Protein A, Protein G, Protein L, or Protein A/G that lacks antibody binding activity, and methods of the modified protein's use for purifying antibodies is provided.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: March 10, 2020
    Assignee: Bio-Rad Laboratories, Inc.
    Inventor: Mark Snyder
  • Patent number: 10513697
    Abstract: A dissolved CO2 change in aqueous solutions affects directly the intracellular pH (pHi) value as it does so by influencing therefore important cellular processes. The enzyme carbonic anhydrase II (CAII) catalyzes the equilibrium of CO2 in aqueous solutions and because it alters the speed at which this equilibrium is reached it was identified as a strong candidate for metabolic engineering. The cell line stably expressing hCAII presented a better initial re-alkalinization of cytoplasm after induced CO2 acid load. The most alkaline pHi value associated to the lowest pHi variations was observed for that cell line in long term increased CO2 levels. In general, the increased CO2 profile triggered the quicker progress of G0G1-cell cycle phase for both transfected and control cell lines.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: December 24, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Betina Da Silva Ribeiro, Markus Emmler, Alexander Jockwer
  • Patent number: 10507340
    Abstract: Provided herein are oral care compositions comprising antifreeze proteins (AFPs) useful in methods of repairing or inhibiting dental erosion, promoting dental remineralization, and/or enhancing the anti-cavity effects of fluoride.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: December 17, 2019
    Assignee: BASF SE
    Inventors: Nina Schneider, Thomas Subkowski, Stefan Jenewein, Marvin Karos, Claus Bollschweiler, Volker Wendel, Jianhong Qiu, LaTonya Kilpatrick-Liverman, Lynette Zaidel
  • Patent number: 10494649
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 3, 2019
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg